| Stephanie Kay Cumpton, CRNA | |
|
1737 Briarcrest Dr, Suite 14, Bryan, TX 77802-2769 | |
| (979) 776-4777 | |
| (979) 776-0588 |
| Full Name | Stephanie Kay Cumpton |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 16 Years |
| Location | 1737 Briarcrest Dr, Bryan, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558507947 | NPI | - | NPPES |
| 199461801 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 582033 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Regional Health Center | Bryan, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Austin Anesthesiology Group Pllc | 0547256497 | 374 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.
Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.
Pandemic flu continues to threaten public health, especially in the wake of the recent emergence of an H7N9 low pathogenic avian influenza strain in humans.
The radial approach for percutaneous coronary interventions (PCI) was developed 20 years ago and is used for more than 50% of procedures in France, Scandinavian countries, the UK, Spain and Italy. Despite the advantages of radial access some countries in Europe such as Germany use radial access for fewer than 10% of PCI.
For years, research to pin down the underlying cause of Alzheimer's Disease has been focused on plaque found to be building up in the brain in AD patients.
› Verified 9 days ago
| Entity Name | Austin Anesthesiology Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598724304 PECOS PAC ID: 0547256497 Enrollment ID: O20040424000086 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.
Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.
Pandemic flu continues to threaten public health, especially in the wake of the recent emergence of an H7N9 low pathogenic avian influenza strain in humans.
The radial approach for percutaneous coronary interventions (PCI) was developed 20 years ago and is used for more than 50% of procedures in France, Scandinavian countries, the UK, Spain and Italy. Despite the advantages of radial access some countries in Europe such as Germany use radial access for fewer than 10% of PCI.
For years, research to pin down the underlying cause of Alzheimer's Disease has been focused on plaque found to be building up in the brain in AD patients.
› Verified 9 days ago
| Entity Name | Emergenchealth Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467970897 PECOS PAC ID: 1355606641 Enrollment ID: O20180608000439 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.
Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.
Pandemic flu continues to threaten public health, especially in the wake of the recent emergence of an H7N9 low pathogenic avian influenza strain in humans.
The radial approach for percutaneous coronary interventions (PCI) was developed 20 years ago and is used for more than 50% of procedures in France, Scandinavian countries, the UK, Spain and Italy. Despite the advantages of radial access some countries in Europe such as Germany use radial access for fewer than 10% of PCI.
For years, research to pin down the underlying cause of Alzheimer's Disease has been focused on plaque found to be building up in the brain in AD patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Kay Cumpton, CRNA 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802-2769 Ph: (979) 776-4777 | Stephanie Kay Cumpton, CRNA 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802-2769 Ph: (979) 776-4777 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.
Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.
Pandemic flu continues to threaten public health, especially in the wake of the recent emergence of an H7N9 low pathogenic avian influenza strain in humans.
The radial approach for percutaneous coronary interventions (PCI) was developed 20 years ago and is used for more than 50% of procedures in France, Scandinavian countries, the UK, Spain and Italy. Despite the advantages of radial access some countries in Europe such as Germany use radial access for fewer than 10% of PCI.
For years, research to pin down the underlying cause of Alzheimer's Disease has been focused on plaque found to be building up in the brain in AD patients.
› Verified 9 days ago
Shelly Rene Eriksson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 | |
Marjorie Shenkir, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 | |
Max T Green, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 | |
Brant Christopher Langlinais, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 | |
Kelly Lynn Sampson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 | |
Stephen Hays, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 | |
Crystal Michelle Price, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1737 Briarcrest Dr, Suite 14, Bryan, TX 77802 Phone: 979-776-4777 Fax: 979-776-0588 |